Evidence map›Paper›PMID 38863886›Full record

ArticleFrontiers in medicine2024

Efficiency of polymyxin B treatment against nosocomial infection: a systematic review and meta-analysis.

Liyuan Peng, Zhongheng Zhang, Xueyan Qi, Yanjun Zhong, Tongwen Sun, Lvlin Chen, Junchen Zhu, Xiangui Lv, Penglin Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Liyuan Peng *Department of Critical Care Medicine, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China.
Zhongheng Zhang *Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Xueyan QiDepartment of Emergency and Critical Care Medicine, Henan Engineering Research Center for Critical Care Medicine, Henan Key Laboratory of Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yanjun ZhongCritical Care Medicine, The Second Xiangya Hospital, Changsha, Hunan, China.
Tongwen SunDepartment of Emergency and Critical Care Medicine, Henan Engineering Research Center for Critical Care Medicine, Henan Key Laboratory of Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Lvlin ChenDepartment of Critical Care Medicine, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China.
Junchen ZhuDepartment of Critical Care Medicine, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China.
Xiangui LvDepartment of Critical Care Medicine, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China.
Penglin MaDepartment of Critical Care Medicine, Guiqian International General Hospital, Guiyang, Guizhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Some cohort studies have explored the effects and safety of polymyxin B (PMB) in comparison to other antibiotics for the treatment of nosocomial infections, yielding inconsistent results. This systematic review aims to explore the effectiveness and safety of PMB and compared it with other antibiotics. Methods: A systematic literature search was conducted in PubMed, Embase, the Cochrane Library, and Web of Science, searching specific terms to identify quantitative cohort studies or RCTs that compared the effects of PMB with other antibiotics in terms of their efficacy and safety. The Newcastle-Ottawa Scale (NOS) was conducted to evaluate the risk of bias of observational studies. Odds ratios with 95% confidence intervals were used for outcome assessment. We evaluated heterogeneity using the Results: A total of 22 observational trials were included in the analysis. The PMB group had a higher mortality rate compared to the control group (odds ratio: 1.84, 95% CI: 1.36-2.50, Conclusion: In patients with nosocomial infections, PMB is not superior to other antibiotics in terms of mortality, specifically when compared to ceftazidime-avibactam. However, PMB demonstrated an advantage in terms of nephrotoxicity compared to colistin.

Indexed as

ceftazidime-avibactamcolistinmeta-analysisnosocomial infectionsPolymyxin Btigecycline

Identifiers

PMID38863886
PMCPMC11165566

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.